Keros Therapeutics (KROS) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$693.5 million.
- Keros Therapeutics' Enterprise Value fell 3067.51% to -$693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$693.5 million, marking a year-over-year decrease of 3067.51%. This contributed to the annual value of -$559.9 million for FY2024, which is 6908.84% down from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Enterprise Value is -$693.5 million, which was down 3067.51% from -$690.2 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Enterprise Value peaked at -$215.6 million during Q2 2022, and registered a low of -$720.5 million during Q1 2025.
- Over the past 5 years, Keros Therapeutics' median Enterprise Value value was -$322.0 million (recorded in 2023), while the average stood at -$381.2 million.
- The largest annual percentage gain for Keros Therapeutics' Enterprise Value in the last 5 years was 1347.77% (2021), contrasted with its biggest fall of 36810.78% (2021).
- Over the past 5 years, Keros Therapeutics' Enterprise Value (Quarter) stood at -$230.0 million in 2021, then decreased by 21.3% to -$279.0 million in 2022, then fell by 18.67% to -$331.1 million in 2023, then plummeted by 69.09% to -$559.9 million in 2024, then decreased by 23.85% to -$693.5 million in 2025.
- Its Enterprise Value stands at -$693.5 million for Q3 2025, versus -$690.2 million for Q2 2025 and -$720.5 million for Q1 2025.